With Trump in, dealmaking is back

A Trump presidency is expected to unlock M&A activity; pharmaceuticals appear poised for a significant resurgence.

TODAY’S STORY

Wall Street expects a Trump presidency to unlock more merger and acquisition (M&A) activity.

Dealmaking has slowed in recent years due to high interest rates, soaring company valuations, and a tight regulatory environment.

Goldman Sachs projects a 20% increase in M&A activity in 2025 over this year.

While all industries should see some uptick, pharmaceuticals appear poised for a significant resurgence. Lina Khan, the Chair of the Federal Trade Commission, has taken a particular interest in the industry over the past few years, arguing monopolies will stifle drug development and hurt consumer choice. Notably, Khan blocked Sanofi’s proposed acquisition of a drug from Maze Therapeutics. The FTC also sued to block Amgen’s $27.8Bn acquisition of Horizon Therapeutics.

With Trump in, Khan is almost certainly out. Dealmaking just might be back.

OUR PICKS

Here are today’s recs to help you live a smarter life…

1. Make your mornings better.

Delicious coffee made in minutes. Brew an 8, 10, or 12 oz. cup at the push of a button. 33% off for a limited time.*

2. Capture every event on the road.

The ROVE R2-4K PRO Dash Cam records precise driving routes, locations, and speed stamps directly on the video as additional evidence.*

3. Perfect for family game night.

Set sail and compete with other settlers to establish supremacy.*

#SHORTS

The AGI bubble is bursting a little bit

@boringbusinesskieran

The AGI bubble is bursting a little bit 📌🎈 #business #techtok #ai #agi #openai #samaltman #google #anthropic #bloomberg #machinelearning #... See more

PREVIOUS STORIES

To read the web version of previous stories, click here

If you have any comments or feedback, just respond to this email.

Thanks for reading,
Kieran & Justin Ryan